Biotechnology

Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing

TOKYO, Oct. 7, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raisingJPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AME...

2025-10-07 21:00 1420

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized...

2025-10-07 20:30 1868

Terumo Blood and Cell Technologies Honored with Corporate Excellence Award at the Asia Pacific Enterprise Awards 2025 Regional Edition

SINGAPORE, Oct. 7, 2025 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) has been recognized with the Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) 2025 Regional Editionorganized by Enterprise Asia, a testament to its unwavering commitment to innovation, ...

2025-10-07 13:25 1344

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health –Abu Dhabi LEHI, Utah, Oct. 6, 2025 /PRNewswire/ -- Halia Therapeutics (The Genetic Resilience Company), a clinical-stage biopharmaceutical compa...

2025-10-06 20:15 1429

FDA Lifts Clinical Hold on NUZ-001

Highlights: * U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS * Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 * IND supported by robust preclinical safety data and comprehensive manufacturing and ...

2025-10-06 14:06 1370

Taiwan Pavilion Fostering Collaborative Innovation in AI, Regenerative Medicine and CDMO at BioJapan 2025

TAIPEI, Oct. 6, 2025 /PRNewswire/ -- The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) , an organization focused on fosteringTaiwan's biotech ecosystem, announced today that it will lead a delegation of 16 biotech industry partners fromTaiwa...

2025-10-06 07:15 2378

Nutromics unveils world-first real-time in vivo multiplexing data at IATDMCT

MELBOURNE, Australia, Oct. 3, 2025 /PRNewswire/ -- Diagnostics company Nutromics has presented the world's first real-time, continuous data on two critical antibiotics - vancomycin and tobramycin - measured simultaneously on the same device in animal models. The breakthrough was unveiled at the ...

2025-10-03 08:48 1526

Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States

* The AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same conditions as the reference product ACTEMRA® (tocilizumab) * AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the FDA * This launch stre...

2025-10-02 20:30 1677

AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing

* Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. * Patented Flagship NB-A002 is a First-in-class DNA...

2025-10-02 19:50 4366

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

* Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 2025 1-3 * MSA is a rare, rapidly progressing, neurodegenerative disease...

2025-10-02 16:41 1452

ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease

BOSTON, Oct. 2, 2025 /PRNewswire/ -- Addressing Critical Unmet Medical Need ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's therapeutics are l...

2025-10-02 14:13 1262

Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India

HYDERABAD, India, Oct. 1, 2025 /PRNewswire/ -- Gene Solutions , a leading genetic testing innovator in Asia, has partnered withAMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnosti...

2025-10-01 20:01 1738

Telix Announces Record-Breaking Presence at EANM 2025

MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (E...

2025-10-01 13:57 1708

Angel Yeast Opens World's First High-Altitude Probiotic Production Facility, Unlocking a New Frontier in Microbial Innovation

SHANNAN, China, Oct. 1, 2025 /PRNewswire/ -- Angel Yeast (SH600298), a global leader in yeast and biotechnology, today announced that its subsidiary Xizang Angel Zhufeng Biotechnology Co., Ltd. ("Angel Zhufeng"), located on the Qing-Zang Plateau, has officially commen...

2025-10-01 10:00 1494

Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities

* Series C led by Junson Capital along with new investor syndicate and existing shareholders * Funding will further advance Full-Life's global radiopharmaceutical pipeline and manufacturing capabilities inBelgium * Additional debt financing provides an alternative financing solution for Ful...

2025-09-30 08:00 1448

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

* HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("...

2025-09-29 20:48 1014

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Viva Biotech announced today that it has been honored...

2025-09-29 17:00 866

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SAN ANTONIO, Sept. 29, 2025 /PRNewswire/ -- Frost & Sullivan

2025-09-29 12:00 1079

The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development

SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...

2025-09-27 10:45 3581

Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth

BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...

2025-09-26 08:47 1571
1 ... 13141516171819 ... 341